-
公开(公告)号：KR100426636B1
公开(公告)日：2004-04-08
申请号：KR1020010027171
申请日：2001-05-18
Applicant: 한국과학기술연구원
IPC: A61K9/00
Abstract: PURPOSE: A process of preparing a gel type composition containing a specified amount of a biocompatible polymer is provided. Whereby, the composition can be used as a local drug delivery system and formulations thereof and release drug from a local portion for 6 days. CONSTITUTION: This gel type composition comprises a phospholipid-based compound, drug and water, wherein the composition additionally contains 3% by weight of one or more biocompatible polymers selected from the group consisting of hyaluronic acid, chitosan and alginic acid. The phospholipid-based compound is one or more selected from a saturated or unsaturated C6-22 phosphatidylcholine-based compound, phosphatidylethanolamine-based compound, phosphatidylserine-based compound and phosphatidic acid-based compound.
Abstract translation: 目的：提供一种制备含有特定量的生物相容性聚合物的凝胶型组合物的方法。 由此，该组合物可以用作局部药物递送系统及其制剂并且将药物从局部释放6天。 构成：该凝胶型组合物包含基于磷脂的化合物，药物和水，其中所述组合物另外含有3重量％的一种或多种选自透明质酸，壳聚糖和海藻酸的生物相容性聚合物。 磷脂类化合物为选自饱和或不饱和C6-22磷脂酰胆碱类化合物，磷脂酰乙醇胺类化合物，磷脂酰丝氨酸类化合物和磷脂酸类化合物中的一种或多种。
-
32.发明公开
公开(公告)号：KR1020040020679A
公开(公告)日：2004-03-09
申请号：KR1020020052346
申请日：2002-08-31
Applicant: 한국과학기술연구원
IPC: A61K47/44
CPC classification number: A61K9/107 , A61K9/0019 , A61K47/30 , A61K47/44 , A61K48/0033 , A61K49/0438
Abstract: PURPOSE: A new oil-in-water type emulsion formulation using an oil phase contrast agent and a cationic polymer allowing effective delivery of a physiologically active substance such as a gene or a drug into cells is provided together with a method for production thereof. The gene or drug delivery formulation for topical application exhibits high transfection efficiency in desired targeted cells for a long period of time in the case of local gene delivery. CONSTITUTION: The complex formulation for effective delivery of a physiologically active substance such as a gene or a drug into targeted cells comprises 10 to 50% by weight of a cationic polymer and 50 to 90% by weight of iodized oils. The binding ratio of the physiologically active substance and cationic polymer is 1:1 to 1:2. The cationic polymer is selected from the group consisting of polylysine, dendrimer, linear polyethyleneimine, branched polyethyleneimine, chitosan, diethylaminoethyl-dextran, polydimethyl and aminoethylmethacrylate and the iodized oils are selected from the group consisting of iodized poppy seed oil, ethiodol and iodized soybean oil.
Abstract translation: 目的：提供一种使用油相造影剂和允许将生理活性物质如基因或药物有效递送到细胞中的阳离子聚合物的新的水包油型乳液制剂及其生产方法。 用于局部应用的基因或药物递送制剂在局部基因递送的情况下在期望的靶细胞中长时间显示高转染效率。 构成：将有效递送诸如基因或药物的生理活性物质的复合制剂包含10至50重量％的阳离子聚合物和50至90重量％的碘化油。 生理活性物质和阳离子聚合物的结合比为1:1至1:2。 阳离子聚合物选自聚赖氨酸，树枝状聚合物，线性聚乙烯亚胺，支化聚乙烯亚胺，壳聚糖，二乙基氨基乙基 - 葡聚糖，聚二甲基和氨乙基甲基丙烯酸酯，碘化油选自碘化罂粟籽油，乙醇碘化物和碘化大豆油 。
-
公开(公告)号：KR1020040009018A
公开(公告)日：2004-01-31
申请号：KR1020020042794
申请日：2002-07-20
Applicant: 한국과학기술연구원
IPC: A61K31/245
CPC classification number: A61K9/5078 , A61K9/0095 , A61K9/5026 , A61K9/5031 , A61K31/14 , A61K31/245 , A61K45/06 , A61K2300/00
Abstract: PURPOSE: Provided is a p-glycoprotein inhibitor which comprises otilonium bromide as an effective ingredient, thereby increasing the absorption of otilonium bromide into the cell and bioavailability of the drug in the living body. CONSTITUTION: A p-glycoprotein inhibitor is characterized by comprising, as an effective ingredient, otilonium bromide that inhibits the activity of p-glycoprotein and increases the absorption of drugs into the cell. The composition is formulated into a sustained release preparation and releases drugs continuously for 12 hours.
Abstract translation: 目的：提供一种P-糖蛋白抑制剂，其包含溴化溴铵作为有效成分，从而增加溴化铵对细胞的吸收和生物体内药物的生物利用度。 构成：P-糖蛋白抑制剂的特征在于包含抑制β-糖蛋白活性的otilonium溴化物作为有效成分，并增加药物对细胞的吸收。 将组合物配制成持续释放制剂并连续释放药物12小时。
-
公开(公告)号：KR1020030023369A
公开(公告)日：2003-03-19
申请号：KR1020010056536
申请日：2001-09-13
IPC: A61K31/335
CPC classification number: A61K49/0452 , A61K9/0019 , A61K31/337 , A61K47/44
Abstract: PURPOSE: A process of preparing a paclitaxel oily composition for chemoembolization by adding paclitaxel to an oily contrast medium and then agitating is provided. The composition is easy to manufacture and sterilize and more physiochemically stable than conventional adriamycin/lipiodol preparation. CONSTITUTION: The paclitaxel oily composition is prepared by mixing 0.0001 to 10mg paclitaxel with 1ml oily contrast medium under sterilization conditions, agitating at room temperature and then sterilized by gamma ray. The oily contrast medium is iodized oil having an iodine content of 30 to 50% selected from iodized poppy seed oil, ethiodol and iodized soybean oil. The composition optionally contains 0.1 to 1ml animal oil such as squalane, vegetable oil such as soybean oil or a mixture thereof, based on 1ml oily contrast medium.
Abstract translation: 目的：提供通过将紫杉醇加入到油性造影剂中然后搅拌来制备用于化学栓塞的紫杉醇油性组合物的方法。 该组合物易于制造和消毒，并且比常规阿霉素/碘油制剂更具生理化学稳定性。 构成：通过在灭菌条件下将0.0001至10mg紫杉醇与1ml油性造影剂混合制备紫杉醇油性组合物，在室温下搅拌，然后用γ射线灭菌。 油性造影剂是选自碘化罂粟籽油，乙醇碘化物和碘化大豆油中碘含量为30〜50％的碘化油。 基于1ml油性造影剂，组合物任选地含有0.1至1ml动物油如角鲨烷，植物油如大豆油或其混合物。
-
公开(公告)号：KR1020020088181A
公开(公告)日：2002-11-27
申请号：KR1020010027171
申请日：2001-05-18
Applicant: 한국과학기술연구원
IPC: A61K9/00
CPC classification number: A61K9/06 , A61K9/0019 , A61K31/196 , A61K31/65 , A61K47/24 , A61K47/36
Abstract: PURPOSE: A process of preparing a gel type composition containing a specified amount of a biocompatible polymer is provided. Whereby, the composition can be used as a local drug delivery system and formulations thereof and release drug from a local portion for 6 days. CONSTITUTION: This gel type composition comprises a phospholipid-based compound, drug and water, wherein the composition additionally contains 3% by weight of one or more biocompatible polymers selected from the group consisting of hyaluronic acid, chitosan and alginic acid. The phospholipid-based compound is one or more selected from a saturated or unsaturated C6-22 phosphatidylcholine-based compound, phosphatidylethanolamine-based compound, phosphatidylserine-based compound and phosphatidic acid-based compound.
Abstract translation: 目的：提供一种制备含有特定量的生物相容性聚合物的凝胶型组合物的方法。 因此，组合物可以用作局部药物递送系统及其制剂，并从局部部分释放药物6天。 构成：该凝胶型组合物包含基于磷脂的化合物，药物和水，其中该组合物另外含有3重量％的一种或多种选自透明质酸，壳聚糖和海藻酸的生物相容性聚合物。 基于磷脂的化合物是选自饱和或不饱和的C6-22磷脂酰胆碱化合物，基于磷脂酰乙醇胺的化合物，磷脂酰丝氨酸基化合物和磷脂酸类化合物中的一种或多种。
-
Patent Agency Ranking
公开(公告)号：KR1020020066776A
公开(公告)日：2002-08-21
申请号：KR1020010007123
申请日：2001-02-13
Applicant: 한국과학기술연구원
IPC: A61K9/10
CPC classification number: A61K9/0095 , A61K9/1075 , A61K9/4858
Abstract: PURPOSE: A process of preparing a peroral administration form for insulin is provided by using monoglycerides, emulsifiers, organic solvents, insulin and an acidic aqueous solution. Therefore, the formulation is excellent in a filling rate of insulin into the administration form and bioavailability as compared to prior art and has improved convenience. CONSTITUTION: A liquid peroral administration form for insulin comprises 0.01 to 20% by weight of insulin, 9 to 90% by weight of one or more monoglycerides, 0.01 to 90% by weight of one or more emulsifiers, 0.01 to 10% by weight of an acidic aqueous solution, 1 to 90% by weight of an organic solvent and 0 to 5% by weight of an additive, and is prepared by dissolving the emulsifier in the organic solvent, adjusting the solution to acidity, adding and agitating insulin powder, adding one or more monoglycerides and removing a volatile organic solvent from the obtained viscose composition.
Abstract translation: 目的：通过使用单酸甘油酯，乳化剂，有机溶剂，胰岛素和酸性水溶液来提供制备胰岛素口服给药形式的方法。 因此，与现有技术相比，该配方在胰岛素与给药形式的填充率和生物利用度方面是优异的，并且具有改进的便利性。 构成：用于胰岛素的液体口服给药形式包含0.01至20重量％的胰岛素，9至90重量％的一种或多种甘油单酯，0.01至90重量％的一种或多种乳化剂，0.01至10重量％ 酸性水溶液，1〜90重量％的有机溶剂和0〜5重量％的添加剂，通过将乳化剂溶解在有机溶剂中，将溶液调节至酸性，加入并搅拌胰岛素粉末， 加入一种或多种单甘油酯并从所得粘胶组合物中除去挥发性有机溶剂。
-
公开(公告)号：KR102117035B1
公开(公告)日：2020-06-01
申请号：KR1020180092555
申请日：2018-08-08
IPC: D06M15/03 , D06B3/10 , D06C3/00 , D06P3/52 , D06M13/292 , D06M101/32
-
-
公开(公告)号：KR101052065B1
公开(公告)日：2011-07-27
申请号：KR1020080101249
申请日：2008-10-15
Applicant: 한국과학기술연구원
Inventor： 남길수 , 최경일 , 김혜란 , 서선희 , 백이연 , 김윤지 , 신희섭 , 김동진 , 배애님 , 정혜진 , 추현아 , 임혜원 , 조용서 , 노은주 , 금교창 , 최기현 , 신계정 , 한호규 , 정찬성 , 이재균 , 남기달 , 강용구 , 김영수 , 박웅서 , 김은경 , 김기선 , 정혜선 , 신동윤 , 송치만
IPC: C07D403/12 , C07D403/10
CPC classification number: C07D231/12 , C07D401/04 , C07D405/04 , C07D405/10 , C07D405/12
Abstract: 본 발명은 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체 및 이의 약제학적으로 허용 가능한 염, 이들 화합물의 제조방법, 그리고 이 화합물이 갖는 칼슘이온 채널 억제 효과에 의한 질환 치료제로 사용하는 의약적 용도에 관한 것이다.
피라졸릴메틸아민-피페라진 유도체, 칼슘이온 채널 조절제, 뉴런, 탈분극화, 급성통증, 만성통증, 신경병증성 통증, 고혈압치료제Abstract translation: 本发明是有效的吡唑基甲胺作为钙离子通道调节剂 - 哌嗪衍生物和化学，以允许它的药学上可接受的盐，在疾病治疗由钙用于生产这些化合物和药物用于化合物工艺通道具有抑制作用 等等。
-
公开(公告)号：KR1020100042111A
公开(公告)日：2010-04-23
申请号：KR1020080101249
申请日：2008-10-15
Applicant: 한국과학기술연구원
Inventor： 남길수 , 최경일 , 김혜란 , 서선희 , 백이연 , 김윤지 , 신희섭 , 김동진 , 배애님 , 정혜진 , 추현아 , 임혜원 , 조용서 , 노은주 , 금교창 , 최기현 , 신계정 , 한호규 , 정찬성 , 이재균 , 남기달 , 강용구 , 김영수 , 박웅서 , 김은경 , 김기선 , 정혜선 , 신동윤 , 송치만
IPC: C07D403/12 , C07D403/10
CPC classification number: C07D231/12 , C07D401/04 , C07D405/04 , C07D405/10 , C07D405/12
Abstract: PURPOSE: A pyrazolylmethylamine-piperazine derivative which is effective as a calcium ion channel modulator is provided to ensure effective activation as an T-type calcium ion channel antagonist and to use as an agent for preventing and treating brain diseases, heart diseases and pain diseases. CONSTITUTION: A pyrazolylmethylamine-peperazine derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating brain diseases, heart diseases or pain diseases by T-type calcium ion channel antagonism contains the pyrazolylmethylamine-peperazine derivative of chemical formula 1 or its pharmaceutically acceptable salt an active ingredient. The brain disease is epilepsy, depression, Parkison's disease, dementia or somnipathy. The heart disease is hypertension, cardiac arrhythmia, myocardial infarction, or congestive failure. The pain disease is chronic pain, acute pain, or neurogenic pain. The pyrazolylmethylamine-peperazine derivative is prepared by binding pyrazolylmethylamine compound of chemical formula 3 with piperazine acetyl halide compound of chemical formula 2.
Abstract translation: 目的：提供作为钙离子通道调节剂有效的吡唑基甲胺 - 哌嗪衍生物，以确保作为T型钙离子通道拮抗剂的有效活化，并用作预防和治疗脑疾病，心脏病和疼痛疾病的药剂。 构成：吡唑基甲胺 - 哌嗪衍生物由化学式1表示。用于通过T型钙离子通道拮抗作用预防和治疗脑疾病，心脏病或疼痛疾病的药物组合物含有化学式1的吡唑基甲基 - 哌嗪衍生物或其药学上可接受的盐 可接受的盐为活性成分。 脑疾病是癫痫，抑郁症，帕金森病，痴呆或嗜睡。 心脏病是高血压，心律失常，心肌梗死或充血性衰竭。 疼痛疾病是慢性疼痛，急性疼痛或神经源性疼痛。 通过将化学式3的吡唑基甲基胺化合物与化学式2的哌嗪乙酰卤化合物结合，制备吡唑基甲胺 - 哌嗪衍生物。
-
-
-
-
-
-
-
-
-
Search Results
63
records
(took 0.026 seconds)
